Recent Updates
Recently added Catalysts
REGN

Regeneron Announces March 2011 Investor Conference Presentations

Key Takeaway: Regeneron Announces March 2011 Investor Conference Presentations

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
2.6%
average across 15 past catalysts
Lead asset
VEGF Trap-Eye
Phase 1 · Diabetic Macular Edema

Full Press Release Details

TARRYTOWN, N.Y.,Feb. 23, 2011/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq:REGN) will webcast management presentations at the following investor conferences:
• Citi 2011 Global Healthcare Conference at9:00 a.m. Eastern TimeonTuesday, March 1, 2011
• RBC Capital Markets' 2011 Healthcare Conference at10:00 a.m. Eastern TimeonWednesday, March 2, 2011
• Cowen and Company 31st Annual Healthcare Conference at1:20 p.m. Eastern TimeonTuesday, March 8, 2011
• Barclays Capital 2011 Global Healthcare Conference at9:00 a.m. Eastern TimeonWednesday, March 16, 2011
The sessions may be accessed through the Company’s web site,www.regeneron.com, on the Investor Relations page.  Archived versions of the presentations will be available for thirty days after the live webcasts.
Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.  In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions and cancer.  Additional information about Regeneron and recent news releases are available on Regeneron's web site atwww.regeneron.com.
Contact Information:
Michael Aberman, M.D. Peter Dworkin
Investor Relations Corporate Communications
914.345.7799 914.345.7800
[email protected] [email protected]
Last updated: Feb 23, 2011